These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding. Venkatesan MM; Ballou C; Barnoy S; McNeal M; El-Khorazaty J; Frenck R; Baqar S PLoS One; 2021; 16(11):e0259361. PubMed ID: 34793505 [TBL] [Abstract][Full Text] [Related]
3. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086 [TBL] [Abstract][Full Text] [Related]
4. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680 [TBL] [Abstract][Full Text] [Related]
5. A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Frenck RW; Baqar S; Alexander W; Dickey M; McNeal M; El-Khorazaty J; Baughman H; Hoeper A; Barnoy S; Suvarnapunya AE; Kaminski RW; Venkatesan MM Vaccine; 2018 Aug; 36(32 Pt B):4880-4889. PubMed ID: 30037478 [TBL] [Abstract][Full Text] [Related]
6. Complement-mediated serum bactericidal activity of antibodies elicited by the Kapulu MC; Nakakana U; Sciré AS; Sarakinou E; Conti V; Rossi O; Acquaviva A; Necchi F; Obiero CW; Martin LB; Bejon P; Njuguna P; Micoli F; Podda A Front Immunol; 2022; 13():971866. PubMed ID: 36203568 [No Abstract] [Full Text] [Related]
12. Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children. Sarker P; Mily A; Ara A; Haque F; Maier N; Wierzba TF; Walker RI; Venkatesan MM; Raqib R J Infect Dis; 2021 Dec; 224(12 Suppl 2):S829-S839. PubMed ID: 34374425 [TBL] [Abstract][Full Text] [Related]
13. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979 [No Abstract] [Full Text] [Related]
14. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines. Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247 [TBL] [Abstract][Full Text] [Related]
15. Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis. Ndungo E; Andronescu LR; Buchwald AG; Lemme-Dumit JM; Mawindo P; Kapoor N; Fairman J; Laufer MK; Pasetti MF Front Immunol; 2021; 12():725129. PubMed ID: 34721387 [No Abstract] [Full Text] [Related]
16. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Barnoy S; Jeong KI; Helm RF; Suvarnapunya AE; Ranallo RT; Tzipori S; Venkatesan MM Vaccine; 2010 Feb; 28(6):1642-54. PubMed ID: 19932216 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766 [TBL] [Abstract][Full Text] [Related]